E-retailer Catch Group has resolved a trade mark lawsuit it lobbed against a popular online classified ads provider over its “Catch of the week” and “Catch of the month” deals.
Telecommunications giant Telstra has taken a Victoria-based green energy company to court, alleging infringement of its trade mark for broadband subsidiary Belong.
Clifford Chance has been targeted by a phishing scam in which fraudsters sent emails purportedly from the global law firm to mislead clients into paying fraudulent bills, and at least one client was duped into paying a substantial amount of phony fees.
Rugby Australia, which manages national rugby union team the Wallabies, has lost its claim to the wallabies.com.au domain, which is owned by a Perth company and features pictures and links to articles about the cute marsupials.
Chemical giant BASF is appealing an IP Australia ruling that allowed US-based Lubrizol Corporation to amend certain claims of its patent for an improved fuel additive.
Maurice Blackburn has agreed to refrain from any marketing or promotion using a replica of the iconic New York statue, Fearless Girl, while it defends a trade mark lawsuit by State Street Global, the US asset management firm that commissioned the original statue.
Australian automotive electronics developer Directed Electronics OE has won access to documents seized from rivals it claims misappropriated its confidential information and infringed its copyright to gain $3.6 million in secret commissions.
Mylan has renewed calls for a temporary injunction against Sun Pharma pending an appeal of a ruling invalidating its patents for Lipidil, and has sued a second generic drug maker, Cipla, over the cholesterol-lowering medication.
AFT Pharmaceuticals has agreed to a court order temporarily restraining it from distributing point of sale material containing updated claims that its painkiller Maxigesic is more effective than other over-the-counter medications.
German pharmaceutical company Boehringer has struck back at a patent lawsuit brought by Teva, filing a cross-claim alleging Teva is threatening to infringe three of its patents related to its blockbuster inhaler Spiriva with the planned launch of a competing inhaler in Australia.